SCHEMBL17873707

SCHEMBL17873707

CC(C)(C)OC(=O)N1C(=O)c2cc(-c3ccnc(Cl)c3)sc2C1(C)C

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 4/20 0.35
DBF4 Q9UBU7 4/20 0.35
AAK1 Q2M2I8 1/20 0.35
RORB Q92753 3/20 0.34
RORC P51449 2/20 0.34
ROCK2 O75116 1/20 0.34
BACE1 P56817 2/20 0.32
BACE2 Q9Y5Z0 1/20 0.32
POLQ O75417 1/20 0.32
POLB P06746 1/20 0.31
PIP4K2A P48426 1/20 0.31
PIP4K2C Q8TBX8 1/20 0.31
JAK2 O60674 1/20 0.31
JAK1 P23458 1/20 0.31
CDK5 Q00535 1/20 0.31
CDK5R1 Q15078 1/20 0.31
AKR1C3 P42330 1/20 0.31
AKR1C2 P52895 1/20 0.31
BUB1 O43683 1/20 0.30
ATR Q13535 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19350424 0.86 CDC7 (0.38) CDC7DBF4RORBRORCROCK2
SCHEMBL17837206 0.84 MAPK3 (0.37) AAK1BACE1BACE2POLB
SCHEMBL17873705 0.80 MAPK1 (0.45) CDC7DBF4
SCHEMBL17873701 0.75 ROCK2 (0.37) CDC7DBF4AAK1RORBROCK2
SCHEMBL17873704 0.75 MAPK3 (0.39) CDC7DBF4RORBRORCROCK2
SCHEMBL17837270 0.74 BUB1 (0.34) BUB1
SCHEMBL21075868 0.74 BUB1 (0.34) BUB1
SCHEMBL17873734 0.73 ROCK2 (0.38) CDC7DBF4AAK1RORBROCK2
SCHEMBL19350375 0.73 MAPK3 (0.38) CDC7DBF4ROCK2BACE1PIP4K2A
SCHEMBL19373780 0.73 ROCK2 (0.38) CDC7DBF4AAK1RORBROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3237420-B1 ERK INHIBITORS LILLY CO ELI (US) 2018-09-26 EP disclosed
US-9879029-B2 ERK inhibitors ELI LILLY AND COMPANY (US) 2018-01-30 US disclosed
US-9879029-B2 ERK inhibitors ELI LILLY AND COMPANY (US) 2018-01-30 US disclosed
US-9879029-B2 ERK inhibitors ELI LILLY AND COMPANY (US) 2018-01-30 US disclosed
EP-3237420-A1 ERK INHIBITORS Eli Lilly and Company (US) 2017-11-01 EP disclosed
US-20170267691-A1 ERK INHIBITORS LILLY CO ELI (US) 2017-09-21 US disclosed
US-20170267691-A1 ERK INHIBITORS LILLY CO ELI (US) 2017-09-21 US disclosed
US-20170267691-A1 ERK INHIBITORS LILLY CO ELI (US) 2017-09-21 US disclosed
WO-2016106009-A1 ERK INHIBITORS ELI LILLY AND COMPANY (US) 2016-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170267691-A1 ERK INHIBITORS MAPK4, MAPK1, MAPK3 CDC7 266/4885DBF4 3705/4885AAK1 365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.